Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: A multicenter study

Circulation

Volumn 126, Issue 24, 2012, Pages 2852-2858

  Tribouilloy, Christophe ^a,b   Rusinaru, Dan ^a   Maréchaux, Sylvestre ^c   Jeu, Antoine ^a   Ederhy, Stéphane ^d   Donal, Erwan ^e   Réant, Patricia ^f,g   Arnalsteen, Elise ^h   Boulanger, Jacques ⁱ   Ennezat, Pierre Vladimir ^j   Garban, Thierry ^k   Jobic, Yannick ^l  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Department of Cardiology ^*  (France)

^c UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h Centre Hospitalier de Beauvais   (France)

ⁱ Centre Hospitalier Compiegne   (France)

^j UNIV LILLE   (France)

^k CHU de Nantes   (France)

^l SERVICE DE RHUMATOLOGIE   (France)

more..

Author keywords

Diabetes mellitus; Drugs; Echocardiography; Regurgitation; Valves

Indexed keywords

BENFLUOREX;

ADULT; AGE DISTRIBUTION; AGED; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; FRANCE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING;

AGED; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; DIABETES MELLITUS; ECHOCARDIOGRAPHY; EUROPE; FEMALE; FENFLURAMINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; SINGLE-BLIND METHOD;

EID: 84870884857     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.111260     Document Type: Article

References (26)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
2. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283: 1703-1709.
3. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008;6:34.
4. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, Bagheri H, Montastruc JL. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol. 2006;20:577-578.
5. Rafel Ribera J, Casanas Munoz R, Anguera Ferrando N, Batalla Sahun N, Castro Cels A, Pujadas Capmany R. Valvular heart disease associated with benfluorex. Rev Esp Cardiol. 2003;56:215-216.
6. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, CarlhantKowalski D, Sitbon O, Simonneau G, Humbert M. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J. 2009;33: 684-688.
7. Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Maréchaux S, Eicher JC, Blanchard-Lemoine B, Rousseau J, Hénon P, Jobic Y, Etienne Y. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Eur J Echocardiogr. 2011;12:265-271.
8. Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE. 2010;5:e10128.
9. Tribouilloy C, Rusinaru D, Henon P, Tribouilloy L, Leleu F, Andréjak M, Sevestre H, Peltier M, Caus T. Restrictive organic mitral regurgitation associated with benfluorex therapy. Eur J Echocardiogr. 2010;11: 614-621.
10. Weill A, Païta M, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2010;19:1256-1262.
11. Fournier A, Zureik M. Estimates of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf. 2012;21:584-585.
12. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E, Monin JL, Pierard LA, Badano L, Zamorano JL. European Association of Echocardiography recommendations for the assessment of valvular regurgitation, part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:223-244.
13. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL. European Association of Echocardiography recommendations for the assessment of valvular regurgitation, part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307-332.
14. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
15. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;12:2265-2281.
16. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet. 2009;374:577-585.
17. Droogmans S, Kerkhove D, Cosyns B, Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr. 2009;10: 467-476.
18. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609-616.
19. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac valve regurgitation. N Engl J Med. 1998;339:719-724.
20. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1988;339: 713-718.
21. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356:6-9.
22. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836-2841.
23. Gueffet JP, Piriou N, Trochu JN. Valvular heart disease associated with benfluorex. Arch Cardiovasc Dis. 2010;103:342-343.
24. Boudes A, Lavoute C, Avierinos JF, Le Dolley Y, Villacampa C, Salem A, Loundou AD, Michel N, Renard S, Habib G. Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease. Eur J Echocardiogr. 2011; 12:688-695.
25. Dahl CF, Allen MR. Regression and progression of valvulopathy associated with fenfluramine and phentermine. Ann Intern Med. 2002; 136:489.
26. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med. 2001;134:261-266.